GlassScriptPhysician profile
Lisa Bright
NPI 1093949760
$3,482.01
in general payments reported to CMS, 2019-2025
18 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 91% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.85 · 2023: $750 · 2024: $1,147 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,419.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $726.91 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $653.09 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $338.37 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $300.04 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Takeda Pharmaceuticals U.S.A., INC. | $230.90 | 2023-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $206.01 | 2023-2025 | Caplyta |
| Abbvie INC. | $172.35 | 2024-2025 | |
| Corium, LLC | $143.03 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $140.69 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $129.58 | 2023-2025 | Uzedy, Austedo Xr |
| Collegium Pharmaceutical, INC. | $99.93 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $68.40 | 2025 | |
| Idorsia Pharmaceuticals US INC | $66.46 | 2022-2025 | Quviviq |
| Janssen Pharmaceuticals, INC | $61.35 | 2024-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $52.34 | 2023-2025 | Fanapt, Hetlioz |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $40.17 | 2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $35.73 | 2024-2025 | Auvelity |
| Indivior INC. | $16.66 | 2024 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Bright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.